Genmab — Marts 2025
-
At the same time, these are 2 professional parties that should be able to put revenues first and therefore I am not that worried about Epcoritamab, not for current indications, nor for potential future plans for autoimmune diseases. But for now I am assuming the other part of the original deal is dead for now (I already sort of was assuming that...). Just like I don't expect any partnerships with JNJ anymore.
-
Regarding 12:24 the problem is that the wording is a wrong interpretation of what Genmab is saying. According to Genmab there was no trade secret in the first place (they call it an alleged trade secret several times) so they are not assuming that Abbvie had any innovation at all
-
Genmab trækkes ind i retssag om tyveri af forretningshemmelighed af amerikansk gigant https://proinvestor.com/investornyt/1295173/genmab-traekkes-ind-i-retssag-om-tyveri-af-forretningshemmelighed-af-amerikansk-gigant
-
Jyske Bank: Genmab – Sagsøgt af partneren AbbVie https://proinvestor.com/investornyt/1295153/jyske-bank-genmab-sagsogt-af-partneren-abbvie
-
From inception he encouraged openness of data and technology, looked for partnerships in academia, healthcare field and with competing pharma / bio. A strategy that backfired to him maybe just a few times to often. I wonder how his worldview has changed the last few years...
-
EL 12:54, lets hope that. It will just make the case muck easier if Gmab has strong proof of independent development of the linker... case close sort of. But that might not be the case. and that make the protections around the alleged secret very importent. If there is no protection of the secret it is not a secret.
-
AACR25 3424 / 19 - DuoBody
-FAPαxDR4 induces tumor cell death through FAPα-dependent, DR4 transactivation-mediated apoptosis https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/8381 -
AACR25 5788 / 15 - Molecular profiling of NSCLC patients associates CT-based radiomic features with a tumor microenvironment favorable for immunotherapy https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/1563
-
AACR25
3093 / 1 - Molecular profiling of tisotumab vedotin-treated patients identified immune pathways associated with clinical activity, supporting the multimodal mechanism of action https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7265 -
AACR25 6075 / 16 - The combination of an EpCAMx4-1BB bispecific antibody with PD-1 blockade exhibits antitumor activity in a murine tumor model unresponsive to each individual antibody https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7895
-
AACR25 6239 / 3 - Modeling and simulation of CRS events in low-risk populations with a rapid ramp-up SUD regimen of epcoritamab https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/5717
-
AACR25 6880 / 24 - Rinatabart sesutecan (PRO1184) in combination with standard-of-care therapy exerted potentiated antitumor activity in preclinical cancer models https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7537
-
AACR25
CT233 / 2 - A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/10602 -
AACR25 7331 / 17 - Antitumor activity of amivantamab in diffuse pleural mesothelioma https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/8400
-
AACR25 3644 / 6 - Mechanistically explainable AI model for predicting synergistic cancer therapy combinations https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/3279
-
Genmab Announces Initiation of Share Buy-Back Program https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind